Shenzhen International BT Leadership Summit

Shenzhen International BT Leadership Summit (simplified Chinese: 深圳国际BT领袖峰会; traditional Chinese: 深圳國際BT領袖峰會) is a biology-focused business conference. It is held each year in September. It is arranged by the Shenzhen Municipal People's Government. It is held at the Shenzhen Convention and Exhibition Center.

The Shenzhen government development emphasizes biology and the life science industry as an important element of economic guidance and industrial restructuring. The government issued an industrial development plan for biology and life science industry to give strong support for policies, funds, projects and talents.

Structure

The Summit is composed of three parts: speeches, dialogue and a professional forum. Under the aim of “Committed to accelerating the integration and development of global biological resources, science and technology, industry, capital”, the summit calls on experts, scholars and entrepreneurs at home and abroad to discuss new models, explore new directions and build a new environment around issues, technology trends, industry information and policy in the development of biology and life science technology and industry.

Previous summits

2017

The Summit was held 21–23 September 2017. Its theme was to develop wisdom and great health, build the new engine of industry. It was supported by the Ministry of science and technology, China Biotechnology Development Center, China Medicinal Biotechnology Association and the China Quality Association for Pharmaceuticals. The sponsors were Shenzhen Development and Reform Commission and Shenzhen Science and Technology Innovation Committee.

Keynote speakers

• Barry Marshall, Nobel prize in Physiology or Medicine in 2005, foreign academicians of Chinese Academy of Engineering, Australian scientists.
• Rao Yi, lifelong tenured professor of Peking University, director of the Science Department of Peking University.

Dialogues

• Development trend and task of innovative drugs
• Opportunity and challenge of big data development of health care

Professional fora

• Transformation and application of nanobiological technology in medical field
• Innovation application and development of big data development of health care
• Prospect of innovation and entrepreneurship of precision medicine
• Tumor molecular diagnosis and individualized treatment
• New directions in investment of immunization therapy
• Development of new cardiovascular and cerebrovascular diagnostic industry
• Key technology forum for generic drug development frontier and consistency evaluation
• Shenzhen Hong Kong health services Development Forum
• Index system of regional health assessment for life economy
• The Sixteenth International Conference on Bioinformatics--- Bioinformatics data mining and Application Forum faced for precision medical services
• Discussion on biopharmaceutical industry based on Microbiology

2016

The theme was “developing green economy and creating a better life”.

Keynotes

• New model of cross - Pacific cooperation in cancer precision medical industry
• Advances in biological therapy and biotechnology drugs

Dialogue

• BT innovation industry circle in the era of big health

Professional forum

• Smart medicine in the era of big data
• Cell therapy leads the revolution of medical technology
• Drug listing permit holder system preach and bio innovation drug research and development forum
• Development and future strategy of medical robot industry
• The “bounce back” of xenotransplantation
• Gene sequencing industry development
• “Shenzhen international Bio Valley” precision medical international collaborative innovation
• Health industry and scientific and technological innovation development in Shenzhen, Hong Kong

Participants

• Dinshaw J. Patel, professor of MemorialSloan-Kettering Cancer Center Fellow of the National Academy of Science, Fellow of American Academy of Arts and Sciences
• Hans Lehrach, Academician of Germany's Academy of Sciences
• Peter. E. Lobie, PhD, Professor, National Cancer Institute, Singapore; Academician, Royal Academy of Sciences, New Zealand
• Robert Desimone Member of US National Academy of Sciences, Doris and Don Berkey Professor, Dept of Brain and Cognitive Sciences, Director of McGovern Institute for Brain Research at MIT
• Byoung S. Kwon, PhD, Investigator, Korea National Cancer Institute
• Christopher Reinhard, Chairman, Taxus Cardium Pharmaceutical Group
• Chen Yuzong, Professor of the National University of Singapore
• David Baghurst, chairman of Isis innovation of science and Technology (HK) Co., Ltd
• Dr. George Ye, founder, Chief Scientific Officer and President of Anogen-Yes Biotech Laboratories
• Guoping Feng, Poitras Professorship of Neuroscience at the Department of Brain and Cognitive Sciences
• Gerard Marriott, PhD, Professor, UC Berkeley, Department of Biophysics
• Hendrik-Jan Schuurman, Consultant and Director, SchuBiomed Consultancy (Utrecht, the Netherlands)
• Ivor Royston, Professor of University of California, San Diego, School of Medicine
• Je Ho Lee, MD, Clinical Professor and Director, Cancer Center/Gynecology, Bundang Cha University Hospital
• Low Kin Huat, Professor of Nanyang Technological University
• Lung-Ji Chang, Director of immunology, Cancer Center in Florida University
• Peng Bin, Director of Novartis Cancer Drug Translational Science Center, Shanghai, China
• Richard Y. Zhao, PhD, Professor, Institute of Microbiology, Immunology, Human Viruses, University of Maryland
• Tadashi Matsumoto, PhD, President and CEO, ReqMed
• Wei-Wei Zhang, MD, PhD, Chairman, Adventin Inc.; Honorary President of US-China Entrepreneurs Association
• Xurong Jiang, PhD, Chief, Quality and Technology, BioVentures, AstraZeneca
• Yves Decadt, PhD, CEO BioLingus
• Yifan Dai, Associate Professor, Thomas E. Starzl Transplantation Institute, University of Pittsburgh
• Yiwu He, PhD, MBA Senior Vice President, Global Head of R&D, BGI
• Gu Ying, Academician of the Chinese Academy of Sciences
• Wei Yuquan, Vice President of Sichuan University, Academician of Chinese Academy of Sciences
• Jizong Zhao, Member of Chinese Academy of Sciences, director of the Department of Neurosurgery, Tiantan hospital
• Zhang Bo, Professor in Tsinghua University, Fellow of the Chinese Academy of Sciences
• Gao Changqing, chief physician of General Hospital of PLA, Academician of Chinese Academy of Engineering
• Lanjuan Li, Academician of Chinese Academy of Engine
• Shi Xuemin, doctoral tutor, Chinese Academy of Engineering
• Qimin Zhan, Member of Chinese Academy of Engineering, Professor at Peking Union Medical College Director of Peking University Health Science Center
• Chen Wei, China International Economic and Exchange Center, director of the Institute of Innovation and Development
• Xun Chen, Independent Director of Board and President of the Special Commission, Qihoo 360 Technology Co
• Zhekuan Fu, Chairman of QF Capital
• Benjamin W. Wah, American Association for the Advancement of Science (AAAS), Provost of the Chinese University of Hong Kong
• Han Weidong, Director of the Laboratory of Immunology, PLA General Hospital (i.e. 301 Hospital)
• Bai Lu Professor and Executive Vice Dean, School of Medicine, Tsinghua University; Research focus on neuroscience, translational research and drug discovery
• Baoyan Liu, Vice president of China Academy of Chinese Medical Sciences
• Hong Liu, Hong Liu, IBM General Manager of China Health and Life Sciences Industry
• Liu Guoqing, the executive director of China International Capital
• Liangxue Lai, Dean, College of Animal Science and Veterinary Medicine, Jilin University
• Zuhong Lu, Country "Thousand Talents Program" Distinguished experts
• Dinggang Li, MD, President, Beijing Daopei Hospital
• Li Xiaoyu, Associate Professor Hong Kong University
• Li XiaoYi, Dr. Lee's Pharmaceutical Holdings Limited chief executive and founder, vice chairman of the Hong Kong Biotechnology Association
• Dr. Jian Ni, CEO, The National Engineering Research Center of Antibody Medicine (CMAB)
• Nianmin Qi, Professor of School of Pharmacy in Shanghai Jiaotong University
• Lingyun Sun, Vice President of Nanjing drum tower hospital affiliated to Nanjing university medical school, Supervisor of Ph.D candidates
• Tian Wei, President of Beijing Ji Shui Tan Hospital
• Mingyuan Wu, CEO of Zhongyuan Union cell gene engineering Corporation Limited
• Wang Hongguang, Advisor, Deputy Director General, Chinese Academy of Science and Technology for Development (CASTED), Ministry of Science and Technology
• Steven Wang, Managing and Founding Partner
• Wang Shuxin, the chief scientist of Shandong Weigao surgical robot Co. Ltd., director of the joint research center of Tianjin University - Weigao group medical robot, Tianjin University professor
• WenXiong Wang, the Chair Professor in the Life Science Division and the Director of Marine Environmental Laboratory in Shenzhen Research Institute of the HKUST
• Min Xue, CEO of United Imaging
• Xu Huafeng, China Health Care Association, vice chairman and secretary general
• Zhengguo Yang, chairman of the board, Shanxi Aierfu ActivTissue Engineering Co., Ltd
• Zhang Lianshan, deputy general manager and global vice president for research and development of Jiangsu Hengrui pharmaceutical co., Ltd
• Liwei Zhang, vice president of Beijing Tian Tan Hospital, Capital Medical University
• Zhang Fenglou, former Deputy Minister of Health, former chairman of the China Health Care Association
• Zhang Ji, chief scientist for new drug research and development of Hopeful Ecological Company pharmaceutical, Guangdong
• Yuan-Ting Zhang, fellow of International Academy for Medical and Biological Engineering
• Karl Tsim, chair professor of Division of Life Science, and the Director of Center for Chinese Medicine R & D at the Hong Kong University of Science and Technology (HKUST)
• Zhiming Cai, Chief Scientist of National ‘‘973’’ Key Basic Research
• Cai Lintao, principal investigator and the director of Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Science
• Jiankui He, chairman Of Direct Genomics Co., Ltd
• Ningzheng Luo, founder and CEO of ‘Your Online Hospital’
• Ye Li, director of Scientific Research and Research Center for Biomedical Information Technology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences
• Li Guanglin, director of institute of advanced integration technology (SIAIT), SIAT
• Chen Qiu,（Chairman of the forum, host） Director of Shenzhen People's Hospital
• Xizhuo Sun, Director of Shenzhen Luohu Hospital Group
• Xiangjun Zhou, Ph.D, Vice CEO of HRYZ BIOTECH Co. Ltd, chief scientist

2015

The theme was “developing green economy and creating a better life”.

Keynotes

• Fight cancer: CarT therapy for cancer
• Translational medicine: opportunities and challenges
• Biotechnology innovation in the era of great health

Dialogues

• Opportunities and challenges in the era of precision medical care
• Biological medicine, medical technology and instrument supervision policy

Professional forum

• The integration of global customers and industry
• Brain & Future
• New techniques and trends in cell therapy and The awarding ceremony of Shenzhen synthetic cell bank, Shenzhen (North Science) regional cell preparation center
• New medical materials and 3D printing
• Internet Finance + Medical Innovation Seminar
• Synthetic biology and industrial applications
• Modernization and internationalization of traditional Chinese Medicine
• Explore the innovation way of Chinese pharmaceutical enterprises in new situation

2014

Keynotes

• The new future of human biology and biomedical research
• Intelligence development of big data and medical health industry

Professional forum

• High end biomedical engineering in the information age
• Chinese medicine and marine biological medicine industry development forum
• Application of biotechnology in modern agricultural economy
• Cell therapy and regenerative medicine
• Personalized medical care in the whole genome era
• Policy innovation in the field of health care